Investigational drug · Phase 3
KVD900
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Hereditary Angioedema.
Phase 3Last checked: Nov 19, 2026Latest source record: Aug 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
0 still active
All registered trials
9
Any phase or sponsor naming "KVD900"
First trial start
2022
Oct 24, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "KVD900", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hereditary Angioedema
Approved drugs for the same conditions: Hereditary angioedema · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "KVD900" as an intervention, largest first.
- An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)Pivotal-lookingCompleted
KalVista Pharmaceuticals, Ltd.Industry
NCT05505916 · 145 participants · Start Oct 24, 2022 · Primary completion May 27, 2026
Drug: KVD900 600 mg; KVD900 300 mg · For: Hereditary Angioedema
Sites: Scottsdale, Arizona; Little Rock, Arkansas; San Diego, California · 71 sites in all
- A Phase III, Crossover Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)Pivotal-lookingCompleted
KalVista Pharmaceuticals, Ltd.Industry
NCT05259917 · 136 participants · Start Feb 22, 2022 · Primary completion Dec 31, 2023
Drug: Placebo; KVD900 600 mg and 1 more · For: Hereditary Angioedema
Sites: Birmingham, Alabama; Scottsdale, Arizona; Little Rock, Arkansas · 66 sites in all
KalVista Pharmaceuticals, Ltd.Industry
NCT07654829 · 100 participants (planned) · Start Aug 17, 2026 · Primary completion Nov 29, 2027
Drug: KVD900 600 mg · For: Hereditary Angioedema
Sites: Colorado Springs, Colorado
KalVista Pharmaceuticals, Ltd.Industry
NCT04208412 · 84 participants · Start Jul 2, 2019 · Primary completion Dec 8, 2020
Drug: KVD900 · For: Hereditary Angioedema
Sites: Scottsdale, Arizona; Centennial, Colorado; Chevy Chase, Maryland · 25 sites in all
KalVista Pharmaceuticals, Ltd.Industry
NCT04349800 · 84 participants · Start Jan 4, 2018 · Primary completion Sep 10, 2018
Drug: KVD900; Placebo to KVD900 · For: Hereditary Angioedema
Sites: Wales, United Kingdom
- Open-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With HAE Type I or IIPivotal-lookingCompleted
KalVista Pharmaceuticals, Ltd.Industry
NCT06467084 · 36 participants · Start Aug 1, 2024 · Primary completion Jan 15, 2026
Drug: KVD900 150 mg; KVD900 300 mg and 1 more · For: Hereditary Angioedema
Sites: Birmingham, Alabama; Scottsdale, Arizona; San Diego, California · 24 sites in all
- PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 TrialPivotal-lookingCompleted
KalVista Pharmaceuticals, Ltd.Industry
NCT05511922 · 11 participants · Start Oct 24, 2022 · Primary completion May 27, 2026
Drug: KVD900 600 mg; Drug: KVD900 300 mg · For: Hereditary Angioedema
Sites: Scottsdale, Arizona; Little Rock, Arkansas; San Diego, California · 61 sites in all
- Treatment of Angioedema Attacks in Adolescent and Adult Patients 12 Years and Older With HAE Type I or II With SebetralstatApproved for marketing
KalVista Pharmaceuticals, Ltd.Industry
NCT06628713
Drug: Sebetralstat · For: Hereditary Angioedema
Sites: Scottsdale, Arizona
KalVista Pharmaceuticals, Ltd.Industry
NCT07216378
Drug: Sebetralstat · For: Hereditary Angioedema
Sites: San Diego, California; Evansville, Indiana; Wheaton, Maryland · 6 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Correction to "Pharmacological Suppression of the Kallikrein Kinin System with KVD900: An Orally Available Plasma Kallikrein Inhibitor for the On-demand Treatment of Hereditary Angioedema".
· Clin Exp Allergy 2026
- Correction to "Sebetralstat (KVD900): A Potent and Selective Small Molecule Plasma Kallikrein Inhibitor Featuring a Novel P1 Group as a Potential Oral On-Demand Treatment for Hereditary Angioedema".
Davie RL, Edwards HJ, Evans DM, et al. · J Med Chem 2025
- An evaluation of sebetralstat as the first oral on-demand therapy for Hereditary Angioedema.
Farkas H, Balla Z · Expert Opin Pharmacother 2025
- Kallikrein inhibitors for angioedema: the progress of preclinical and early phase studies.
Farkas H, Balla Z · Expert Opin Investig Drugs 2024
- Sebetralstat (KVD900): A Potent and Selective Small Molecule Plasma Kallikrein Inhibitor Featuring a Novel P1 Group as a Potential Oral On-Demand Treatment for Hereditary Angioedema.
Davie RL, Edwards HJ, Evans DM, et al. · J Med Chem 2022
- Pharmacological suppression of the kallikrein kinin system with KVD900: An orally available plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema.
Duckworth EJ, Murugesan N, Li L, et al. · Clin Exp Allergy 2022
Also in development for Hereditary Angioedema
- siRNAADX-038, ADX-324Phase 37 trials
ADARx Pharmaceuticals, Inc. · Hereditary Angioedema, HAE, Hereditary Angioedema - Type 1
- DeucrictibantPHVS416, PHA121Phase 35 trials
Pharvaris Netherlands B.V. · Hereditary Angioedema (HAE), Hereditary Angioedema, Hereditary Angioedema Type I
- NTLA-2002Phase 31 trial
Intellia Therapeutics · Hereditary Angioedema
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.